Software company unblu announced that it has partnered with consulting company SOFGEN to deliver next generation live collaboration solutions to the Asian market. Based in Sarnen in canton Obwalden, unblu offers co-browsing software solutions for the retail and the banking sectors.
Swiss biotech company ObsEva announces the appointment of a new Chief Financial Officer, Timothy M. Adams. Mr. Adams will be located in the Company’s U.S. headquarters in Boston, Massachusetts. In addition the company reported about the successful completion of Phase 1 First-in-Women Study of OBE022 for the treatment of preterm labor.
Technology Fund announces that it closed 2016 successfully with 26 loan Guarantees granted to startups and SMEs developing technologies for the reduction of greenhouse emissions. The organisation will continue to focus its efforts and energy on making 2017 a success too.
Disponible en téléchargement depuis le 11 janvier sur l’App Store et Google Play, Towaga, le nouveau jeu 100 % swiss-made de Sunnyside Games, financé par la communauté du crowdfunding suisse, affiche de grandes ambitions. Après le succès international de leur précédent jeu « The Firm », Sunnyside vise le million de téléchargements pour Towaga, un objectif ambitieux, mais réalisable au vu de l’engouement des joueurs et des premiers résultats.
The Lausanne based startup Teleport offers a SaaS platform that enables users to create interactive videos. Two months ago, the startup was selected to participate in the American accelerator “500 startups”. Gavrilo Bozovic, CEO of Teleport, shares his experience and achievements in this interview.
DECENT is an Open-Source decentralized content distribution platform that utilizes Blockchain to ensure trust and security for content creators and enterprises. After the raising over $4.2 million worth of Bitcoins from their Initial Coin Offering, the startup expanded to China and closed additional partnerships.
Xigen, a SwissCompany developing therapeutic peptides for the treatment of inflammatory diseases, announced the online publication of successful Phase II results for its lead compound Brimapitide (XG-102) in the American Journal of Ophthalmology.